"The Grant for Fertility Innovation reflects our unprecedented commitment to improve outcomes for patients in need of new fertility solutions," said Dr. Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at the biopharmaceutical business of Merck KGaA, Darmstadt, Germany. "The GFI program has already enabled advanced researchers to accelerate scientific discovery and translational work to fertility care by leveraging an impactful global network of expertise across the academic and industry continuum."
The GFI awardees were announced during a ceremony at ESHRE on July 5th.
- Stephen Andrew Krawetz, Ph.D. - Wayne State University School of Medicine, Detroit, USA – Project "A Retrospective Controlled Cohort Study of Sperm RNAs Guiding the 2 Treatment of the Idiopathic Infertile couple"
- Lynne O'Shea, B.Sc. (Hons.), Ph.D. - UCD School of Medicine and Medical Science, University College Dublin, Ireland – Project "Using a biomarker of oocyte quality to improve embryo selection during assisted reproduction"
- Paola Piomboni, PhD- University of Siena, Italy – Project "Exosomal Profile of the Receptive Endometrium: A source of non-invasive biomarkers for Guiding of a Successful Embryo Implantation"
- Qingling Yang received his Ph.D. – Reproductive Medical Center of the first Affiliated Hospital of Zhengzhou University, China - Project "Telomere length test of cell free genomic DNA in spent embryo medium as a non-invasive biomarker for assessing embryo developmental potential"
- Professor Ernest Hung Yu Ng Professor William Shu -biu Yeung – University of Hong Kong, China – Project "Human embryonic stem cell-derived trophoblastic spheroids (BAP-EB) as a predictive tool for endometrial receptivity and pregnancy rate of in vitro fertilization treatment"
- Professor Fulvio Zullo - University Magna Graecia of Catanzaro, Italy – Project "Periostin a new non-invasive parameter for evaluating oocyte/blastocyst quality and its impact on endometrial receptivity"
About EMD Serono, Inc.
EMD Serono is the biopharma business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck KGaA, Darmstadt, Germany, name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Erin-Marie Beals, 1-781-681-2850
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emd-serono-commits-15-million-to-the-grant-for-fertility-innovation-gfi-for-201617-300294669.html
SOURCE EMD Serono